ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Other Noncurrent Liabilities
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Other Noncurrent Liabilities of -$733.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was -$315.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$418.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$404.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$479.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$1.91M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$2.07M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$2.35M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$977.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$733.00K 10-Q · filed 2026-08-06 | -$1.14M derived: sum of 3 quarters · filed 2026-08-06 | -$1.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$418.00K 10-Q · filed 2026-05-08 | -$822.00K derived: sum of 2 quarters · filed 2026-05-08 | -$1.30M derived: sum of 3 quarters · filed 2026-05-08 | -$1.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$883.00K derived: sum of 2 quarters · filed 2026-03-09 | -$1.40M derived: sum of 3 quarters · filed 2026-08-06 | -$1.91M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$479.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$999.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.51M 10-Q · filed 2025-11-07 | -$2.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.03M 10-Q · filed 2026-08-06 | -$1.52M derived: sum of 3 quarters · filed 2026-08-06 | -$2.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$507.00K 10-Q · filed 2026-05-08 | -$1.00M derived: sum of 2 quarters · filed 2026-05-08 | -$1.48M derived: sum of 3 quarters · filed 2026-05-08 | -$1.95M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$974.00K derived: sum of 2 quarters · filed 2026-03-09 | -$1.44M derived: sum of 3 quarters · filed 2026-03-09 | -$2.07M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$478.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$945.00K derived: sum of 2 quarters · filed 2025-11-07 | -$1.57M 10-Q · filed 2025-11-07 | -$1.94M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | -$467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.10M 10-Q · filed 2025-08-12 | -$1.46M derived: sum of 3 quarters · filed 2026-03-09 | -$2.96M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$630.00K 10-Q · filed 2025-05-08 | -$996.00K derived: sum of 2 quarters · filed 2026-03-09 | -$2.50M derived: sum of 3 quarters · filed 2026-03-09 | -$2.79M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.86M derived: sum of 2 quarters · filed 2026-03-09 | -$2.16M derived: sum of 3 quarters · filed 2026-03-09 | -$2.35M 10-K · filed 2026-03-09 |
| 2023-09-30 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.80M derived: sum of 2 quarters · filed 2024-11-07 | -$1.99M 10-Q · filed 2024-11-07 | -$2.13M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | -$297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$488.00K 10-Q · filed 2024-08-12 | -$629.00K derived: sum of 3 quarters · filed 2025-03-06 | -$893.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$191.00K 10-Q · filed 2024-05-09 | -$332.00K derived: sum of 2 quarters · filed 2025-03-06 | -$596.00K derived: sum of 3 quarters · filed 2025-03-06 | -$872.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$405.00K derived: sum of 2 quarters · filed 2025-03-06 | -$681.00K derived: sum of 3 quarters · filed 2025-03-06 | -$977.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$540.00K derived: sum of 2 quarters · filed 2023-11-13 | -$836.00K 10-Q · filed 2023-11-13 | -$3.60M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$572.00K 10-Q · filed 2023-08-10 | -$3.33M derived: sum of 3 quarters · filed 2024-03-07 | -$3.56M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | -$296.00K 10-Q · filed 2023-05-11 | -$3.06M derived: sum of 2 quarters · filed 2024-03-07 | -$3.29M derived: sum of 3 quarters · filed 2024-03-07 | -$1.29M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$2.99M derived: sum of 2 quarters · filed 2024-03-07 | -$990.00K derived: sum of 3 quarters · filed 2024-03-07 | -$698.00K 10-K · filed 2024-03-07 |
| 2021-09-30 | -$228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.77M derived: sum of 2 quarters · filed 2022-11-08 | $2.06M 10-Q · filed 2022-11-08 | $2.06M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.29M 10-Q · filed 2022-08-08 | $2.29M derived: sum of 3 quarters · filed 2023-03-09 | $2.42M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $292.00K 10-Q · filed 2022-05-09 | $293.00K derived: sum of 2 quarters · filed 2023-03-09 | $423.00K derived: sum of 3 quarters · filed 2023-03-09 | $315.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $131.00K derived: sum of 2 quarters · filed 2023-03-09 | $23.00K derived: sum of 3 quarters · filed 2023-03-09 | -$4.00K 10-K · filed 2023-03-09 |
| 2020-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $22.00K derived: sum of 2 quarters · filed 2021-11-12 | -$5.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$135.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$27.00K 10-Q · filed 2021-05-17 | |||
| 2019-09-30 | $1.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $136.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |